Page 205 - Haematologica Vol. 107 - September 2022

ARTICLE - ITP antibody predicts desialylation and apoptosis
S.S. Zheng et al.
mune thrombocytopenic purpura in the General Practice Re-
search Database. Br J Haematol. 2009;145(2):235-244. 27.
8. Moulis G, Palmaro A, Montastruc JL, Godeau B, Lapeyre-Mestre
M, Sailler L. Epidemiology of incident immune thrombocytope-
nia: a nationwide population-based study in France. Blood. 2014;124(22):3308-3315. 28.
9. Audia S, Mahévas M, Nivet M, Ouandji S, Ciudad M, Bonnotte B. Immune thrombocytopenia: recent advances in pathogenesis
and treatments. Hemasphere. 2021;5(6):e574-e574. 29.
10. Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost. 2006;4(11):2377-2383.
11. Harrington WJ, Minnich V, Hollingsworth JW, Moore CV. Demon- 30. stration of a thrombocytopenic factor in the blood of patients
with thrombocytopenic purpura. J Lab Clin Med. 1951;38(1):1-10.
12. Schwartz RS. Immune thrombocytopenic purpura--from agony
to agonist. N Engl J Med. 2007;357(22):2299-2301. 31.
13. Shulman NR, Marder VJ, Weinrach RS. Similarities between
known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic
and isotopic studies. Ann N Y Acad Sci. 1965;124(2):499-542. 32.
14. Cines DB, Cuker A, Semple JW. Pathogenesis of immune throm- bocytopenia. Presse Med. 2014;43(4P2):e49-e59.
15. Semple JW, Rebetz J, Maouia A, Kapur R. An update on the pa- thophysiology of immune thrombocytopenia. Curr Opin Hema- 33. tol. 2020;27(6):423-429.
16. Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T-
cell changes in patients with idiopathic thrombocytopenic pur-
pura receiving B cell-depleting therapy with rituximab. Blood. 34. 2008;112(4):1147-1150.
17. Liu B, Zhao H, Poon MC, et al. Abnormality of CD4(+)CD25(+)
regulatory T cells in idiopathic thrombocytopenic purpura. Eur J 35. Haematol. 2007;78(2):139-143.
18. Ling Y, Cao X, Yu Z, Ruan C. Circulating dendritic cells subsets
and CD4+Foxp3+ regulatory T cells in adult patients with 36. chronic ITP before and after treatment with high-dose dexame- thasome. Eur J Haematol. 2007;79(4):310-316.
19. Olsson B, Andersson PO, Jernas M, et al. T-cell-mediated cyto- 37. toxicity toward platelets in chronic idiopathic thrombocyto-
penic purpura. Nat Med. 2003;9(9):1123-1124.
20. Zhang F, Chu X, Wang L, et al. Cell-mediated lysis of autologous 38. platelets in chronic idiopathic thrombocytopenic purpura. Eur J Haematol. 2006;76(5):427-431.
21. Zhao C, Li X, Zhang F, Wang L, Peng J, Hou M. Increased cyto- 39. toxic T-lymphocyte-mediated cytotoxicity predominant in pa-
tients with idiopathic thrombocytopenic purpura without
platelet autoantibodies. Haematologica. 2008;93(9):1428-1430.
22. Ma L, Simpson E, Li J, et al. CD8+ T cells are predominantly pro- 40. tective and required for effective steroid therapy in murine
models of immune thrombocytopenia. Blood.
2015;126(2):247-256.
23. Swinkels M, Rijkers M, Voorberg J, Vidarsson G, Leebeek FWG, 41. Jansen AJG. Emerging concepts in immune thrombocytopenia.
Front Immunol. 2018;9:880.
24. Leytin V, Mykhaylov S, Starkey AF, et al. Intravenous immuno-
globulin inhibits anti-glycoprotein IIb-induced platelet apopto-
sis in a murine model of immune thrombocytopenia. Br J 42. Haematol. 2006;133(1):78-82.
25. Winkler J, Kroiss S, Rand ML, et al. Platelet apoptosis in paedi- atric immune thrombocytopenia is ameliorated by intravenous immunoglobulin. Br J Haematol. 2012;156(4):508-515.
26. Goette NP, Glembotsky AC, Lev PR, et al. Platelet apoptosis in 43. adult immune thrombocytopenia: insights into the mechanism
of damage triggered by auto-antibodies. PLoS One.
2016;11(8):e0160563.
Nieswandt B, Bergmeier W, Rackebrandt K, Gessner JE, Zirngibl H. Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood. 2000;96(7):2520-2527.
Li J, Van Der Wal DE, Zhu G, et al. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nat Commun. 2015;6:7737.
Chan H, Moore JC, Finch CN, Warkentin TE, Kelton JG. The IgG subclasses of platelet-associated autoantibodies directed against platelet glycoproteins IIb/IIIa in patients with idiopathic thrombocytopenic purpura. Br J Haematol. 2003;122(5):818-824. Webster ML, Sayeh E, Crow M, et al. Relative efficacy of intra- venous immunoglobulin G in ameliorating thrombocytopenia in- duced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies. Blood. 2006;108(3):943-946.
Go RS, Johnston KL, Bruden KC. The association between pla- telet autoantibody specificity and response to intravenous im- munoglobulin G in the treatment of patients with immune thrombocytopenia. Haematologica. 2007;92(2):283-284.
Peng J, Ma SH, Liu J, et al. Association of autoantibody specifi- city and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study. J Thromb Haemost. 2014;12(4):497-504.
Cantoni S, Carpenedo M, Nichelatti M, et al. Clinical relevance of antiplatelet antibodies and the hepatic clearance of platelets in patients with immune thrombocytopenia. Blood. 2016;128(17):2183-2185.
Rumjantseva V, Grewal PK, Wandall HH, et al. Dual roles for he- patic lectin receptors in the clearance of chilled platelets. Nat Med. 2009;15(11):1273-1280.
Zhang H, Nimmer PM, Tahir SK, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 2007;14(5):943-951.
Marini I, Zlamal J, Faul C, et al. Autoantibody-mediated desialy- lation impairs human thrombopoiesis and platelet lifespan. Haematologica. 2021;106(1):196-207.
Zheng SS, Perdomo JS, Leung HHL, Yan F, Chong BH. Acquired Glanzmann thrombasthenia associated with platelet desialyla- tion. J Thromb Haemost. 2020;18(3):714-721.
Zheng SS, Perdomo JS, Ahmadi Z, Chong BH. Indirect detection of anti-platelet antibodies in immune thrombocytopenia. Pa- thology. 2021;53(6):759-762.
Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune throm- bocytopenic purpura of adults and children: report from an in- ternational working group. Blood. 2009;113(11):2386-2393. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of pri- mary immune thrombocytopenia. Blood Adv. 2019;3(22):3780-3817.
Brighton TA, Evans S, Castaldi PA, Chesterman CN, Chong BH. Prospective evaluation of the clinical usefulness of an antigen- specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood. 1996;88(1):194-201.
Liang SX, Pinkevych M, Khachigian LM, Parish CR, Davenport MP, Chong BH. Drug-induced thrombocytopenia: development of a novel NOD/SCID mouse model to evaluate clearance of circu- lating platelets by drug-dependent antibodies and the efficacy of IVIG. Blood. 2010;116(11):1958-1960.
Al-Samkari H, Rosovsky RP, Karp Leaf RS, et al. A modern reas- sessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. Blood Adv. 2019;4(1):9-18.
Haematologica | 107 September 2022
2204